The research, led by corresponding authors Zhe Yang and Rudi Mao, with Pengfei Zhang, Ying Zhang and Chen Li as co-first authors, set out to answer a question that has long frustrated oncologists: why do seemingly similar esophageal tumors respond so differently to the same dose of radiation? The answer, the study suggests, lies not in a single mutation or pathway but in the collective behavior of distinct subpopulations of tumor cells, and in the way those cells reshape the immune landscape around them when radiation pressure is applied.

Methodologically, the study is a showcase of how modern computational biology can extract signal from the enormous noise of cancer genomics. The team combined single-cell RNA sequencing, which profiles gene expression in individual cells and thereby reveals the full cellular diversity of a tumor, with bulk RNA sequencing, which measures average gene expression across an entire tissue sample. Each approach has well-known limitations on its own: single-cell data are rich in resolution but expensive and technically demanding, while bulk data are abundant and clinically practical but blur the contributions of individual cell types together. Integrating the two is widely regarded as one of the most powerful strategies in contemporary oncology research, because it allows findings made at single-cell resolution to be tested against large patient cohorts.

To perform that integration, the researchers used an algorithm called scAB, which is designed to fuse transcriptomic datasets of different resolutions and identify genes associated with a specific biological condition, in this case the response of esophageal cancer cells to radiotherapy. The scAB analysis revealed significant cellular and molecular heterogeneity within esophageal squamous cell carcinoma, with distinct subpopulations of tumor cells linked to radiation resistance. In other words, within a single patient’s tumor, there exist cells that are intrinsically better equipped to survive a course of radiation, and these cells carry a recognizable transcriptional fingerprint.

From this pool of candidate genes, the team applied two machine learning methods to narrow the field: random forest and LASSO regression. Both are standard tools for feature selection in high-dimensional biological data, where thousands of genes must be evaluated and only a handful are likely to be genuinely informative. Random forest builds many decision trees on random subsets of the data and identifies genes that consistently predict the outcome of interest, while LASSO applies a penalization technique that drives the coefficients of uninformative genes to zero, leaving only the strongest predictors. The convergence of these two independent algorithms on the same shortlist gave the researchers confidence that the genes they identified were not statistical artifacts.

Two genes emerged from this computational gauntlet: MAP1LC3B and HSD17B10. MAP1LC3B encodes a protein central to autophagy, the cellular recycling process by which cells break down damaged components and, crucially, survive periods of severe stress. Radiation kills cells largely by inducing catastrophic DNA damage and oxidative stress, and autophagy is one of the principal mechanisms by which stressed cells hold themselves together long enough to repair or adapt. HSD17B10, by contrast, encodes an enzyme involved in mitochondrial metabolism, participating in the breakdown of fatty acids and amino acids and influencing the energy economy of the cell. A tumor cell that can rewire its metabolism under radiation stress has a marked survival advantage, which makes HSD17B10 a plausible contributor to treatment resistance.

The functional importance of these two genes was not left at the level of correlation. The researchers carried out experiments both in vitro, using cultured cells, and in vivo, using animal models, to test whether MAP1LC3B and HSD17B10 actually drive the behaviors predicted by the sequencing data. The results supported a dual role: the two genes regulate cell survival under radiation stress and also contribute to tumor metastasis, the process by which cancer cells detach from the primary tumor, travel through the body and establish new colonies. The link between treatment resistance and metastatic potential is one of the most clinically troubling aspects of cancer biology, because it means that surviving radiotherapy may select for cells that are also better at spreading.

Equally significant was what the study found when it examined the tumor microenvironment, the complex ecosystem of immune cells, fibroblasts and blood vessels that surrounds and infiltrates a tumor. Immune infiltration analysis showed altered patterns of immune cell presence in tumors with high expression of the two signature genes, suggesting that the microenvironment itself may contribute to radiation resistance. This observation fits into a broader and rapidly growing body of evidence that the immune context of a tumor is not a passive backdrop but an active participant in treatment response. Radiation does not act on tumor cells in isolation; it also reshapes inflammatory and immune signaling, and a tumor microenvironment that suppresses immune attack can shield residual cancer cells from both radiation and immunotherapy.

The clinical implications of the study rest on a striking expression pattern: MAP1LC3B and HSD17B10 were found to be significantly overexpressed in esophageal squamous cell carcinoma tumor tissues compared with healthy tissue, and high expression of both genes correlated with poor prognosis and radiotherapy resistance. This combination of properties, differential expression in tumors, association with survival outcomes and mechanistic involvement in resistance, is precisely the profile sought in a biomarker. If validated in larger and more diverse patient cohorts, a test based on these two genes could eventually help clinicians identify, before treatment begins, which patients are unlikely to benefit from radiotherapy alone and might instead require intensified multimodal therapy, dose escalation or alternative strategies such as immunotherapy combinations.

The study also points toward therapeutic intervention. Genes that actively promote resistance are, in principle, druggable targets, and inhibiting their function could sensitize tumors to radiation. Autophagy modulation, in particular, has long been explored as a strategy to enhance the efficacy of cancer therapy, and the new findings give that effort a specific, data-driven anchor in esophageal cancer. Metabolic enzymes such as HSD17B10 are similarly attractive targets, although the authors are careful to frame their work as identifying potential biomarkers and informing future strategies rather than delivering a ready-made treatment. The research was supported by funding from the Shandong Medical Association, the Beijing Life Oasis Public Service Center and the Wu Jieping Medical Foundation, and was conducted with institutional ethics approval and informed patient consent.

Esophageal squamous cell carcinoma remains a devastating diagnosis worldwide, with particularly high incidence in parts of East Asia, and resistance to radiotherapy is a major reason why long-term survival rates have been so difficult to improve. What this study demonstrates is that the tools now exist to dissect that resistance at single-cell resolution, to validate the resulting hypotheses with machine learning and laboratory experiments, and to translate the findings into a short list of genes that could guide patient stratification and drug development. The convergence of single-cell genomics, bulk sequencing and machine learning, exemplified by this work, is rapidly becoming the standard playbook for attacking one of oncology’s most stubborn problems: the tumor that refuses to die under the beam. Whether MAP1LC3B and HSD17B10 ultimately become the basis of a clinical test or a therapeutic target will depend on the validation studies that must now follow, but the road map from radiation resistance to its molecular roots has rarely been drawn so clearly.

Subject of Research: Molecular mechanisms of radiotherapy resistance in esophageal squamous cell carcinoma identified through integrated single-cell and bulk RNA sequencing with machine learning

Article Title: Machine learning-driven single-cell and bulk RNA sequencing integration unveils key genes modulating radiosensitivity and tumor progression in esophageal squamous cell carcinoma

Article References: Zhang, P., Zhang, Y., Li, C., Li, M., Liao, J., Liu, T., Zhou, Y., Zhang, Y., Yang, Z., & Mao, R. (2026). Machine learning-driven single-cell and bulk RNA sequencing integration unveils key genes modulating radiosensitivity and tumor progression in esophageal squamous cell carcinoma. Cancer Cell International. https://doi.org/10.1186/s12935-026-04476-z

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04476-z

Keywords: esophageal squamous cell carcinoma, radiotherapy resistance, single-cell RNA sequencing, bulk RNA sequencing, machine learning, MAP1LC3B, HSD17B10, autophagy, tumor microenvironment, immune infiltration, tumor metastasis, biomarkers

The molecule in question is PD-1, or programmed cell death protein 1, a receptor best known as the target of the blockbuster class of cancer immunotherapies called immune checkpoint inhibitors. PD-1 normally acts as a molecular brake on immune responses, and tumors exploit this brake by co-opting the PD-1/PD-L1 axis to paralyze cytotoxic T lymphocytes, the immune system’s primary tumor-killing cells. What makes the new findings so provocative is that the researchers found radiotherapy itself, a treatment intended to unleash anti-tumor immunity, drives PD-1 expression onto tumor-associated monocytes, converting these cells into immunosuppressive agents that undermine the very immune attack radiation is supposed to provoke.

Monocytes are circulating white blood cells that can be recruited into tissues, including tumors, where they differentiate into macrophages and related myeloid cells. Within the tumor microenvironment, these myeloid cells often take on a suppressive phenotype, dampening T cell activity and fostering an immunologically cold milieu that resists both immunotherapy and other treatments. The new study demonstrates that after radiotherapy, a distinct subset of tumor-associated monocytes upregulates PD-1, and that these PD-1-positive monocytes actively suppress the anti-tumor activity of CD8-positive T cells, the cytotoxic lymphocytes responsible for recognizing and destroying cancer cells.

Perhaps the most technically significant contribution of the work is the delineation of the signaling pathway that connects radiation to PD-1 induction on monocytes. According to the researchers, radiotherapy triggers the adenosine-A2AR-cAMP-PKA-NF-κB axis. In this cascade, adenosine, a purine nucleoside that accumulates in stressed and damaged tissues, engages the A2A adenosine receptor (A2AR) on the monocyte surface. Receptor activation raises intracellular cyclic AMP (cAMP), which in turn activates protein kinase A (PKA), ultimately engaging the transcription factor NF-κB to drive PD-1 expression. This pathway is a classic example of how tissue damage signals can be hijacked by tumors: adenosine is abundant in the hypoxic, metabolically stressed environment of irradiated tumors, and the study shows that this damage-associated molecule becomes the trigger for an immunosuppressive monocyte program.

The functional consequences of this conversion are substantial. When PD-1-positive monocytes accumulate after radiation, they suppress the activity of CD8-positive T cells, blunting the immune-mediated tumor killing that radiation therapy is known to promote through mechanisms such as immunogenic cell death and antigen release. In other words, radiation delivers a double-edged signal: it damages tumor cells in ways that should alert the immune system, but it simultaneously generates a myeloid cell population that mutes that alert. This may help explain a long-standing puzzle in radiation oncology, namely why the much-discussed abscopal effect, in which localized radiation provokes systemic tumor regression, occurs so rarely in clinical practice.

Critically, the researchers did not stop at mechanistic description. They showed that targeting this PD-1-positive monocyte subset enhanced the efficacy of radiotherapy in their experimental models, suggesting that depleting or inhibiting these cells could convert a partially resistant tumor into one that responds robustly to radiation. This therapeutic implication is significant because it points toward combination strategies: rather than simply escalating radiation doses, which risks toxicity, clinicians could in principle pair standard radiotherapy with agents that prevent monocyte PD-1 induction or eliminate the suppressive subset altogether.

The clinical relevance of the findings received direct support from human tissue analysis. The team examined tissues from patients whose tumors had proven resistant to radiotherapy and found elevated infiltration of PD-1-positive monocytes compared with what would be expected in a responsive setting. This correlation between the presence of the suppressive monocyte subset and treatment failure in patients elevates the work beyond a laboratory observation and suggests that the pathway identified in preclinical models operates in human disease. If validated in larger cohorts, PD-1-positive monocyte infiltration could serve as a biomarker predicting which patients are likely to resist radiotherapy and therefore need combination treatment from the outset.

The study also reframes the ongoing conversation about PD-1 as a therapeutic target. Checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 antibodies were developed to release the brake on T cells, and they have transformed outcomes in melanoma, lung cancer and many other malignancies. But the new findings indicate that PD-1 biology extends beyond T cells: myeloid cells expressing PD-1 after radiation represent a separate, radiation-induced reservoir of immunosuppression. This raises intriguing questions about whether PD-1-targeting drugs exert some of their effects through monocytes rather than exclusively through T cells, and whether patients receiving radiotherapy might benefit from checkpoint blockade precisely because it neutralizes the radiation-induced monocyte program.

From a broader perspective, the work exemplifies a growing appreciation that the success or failure of cancer treatment is decided not only by the intrinsic sensitivity of tumor cells but by the ecosystem surrounding them. The tumor microenvironment is a dense network of immune, stromal and vascular components that respond dynamically to therapy. Radiation-induced cell death releases damage-associated molecular patterns, including adenosine, and the new study shows how one such signal is translated, through a defined receptor-second messenger-transcription factor cascade, into a durable immunosuppressive state. Understanding these feedback loops at the molecular level is essential if combination therapies are to be designed rationally rather than empirically.

For patients and clinicians, the immediate takeaway is one of cautious optimism. The identification of the adenosine-A2AR-cAMP-PKA-NF-κB pathway and the suppressive PD-1-positive monocyte subset it generates offers multiple potential points of intervention, from adenosine receptor antagonists to strategies that deplete the monocyte subset, and the demonstration that targeting these cells boosts radiotherapy efficacy provides a proof of principle. Translating that principle into the clinic will require further validation, safety assessment and well-designed trials, but the study supplies a clear mechanistic target for overcoming one of radiotherapy’s most persistent limitations. As the authors conclude, depleting this distinct immunosuppressive monocyte subset that accumulates after radiation represents a promising strategy to overcome resistance and strengthen anti-tumor immunity, a conclusion that could reshape how radiation oncology and immunotherapy are combined in the years ahead.

Subject of Research: Radiotherapy-induced PD-1 expression on tumor-associated monocytes and its role in immunosuppression and radioresistance

Article Title: Radiotherapy drives PD-1 expression on monocytes to attenuate anti-tumor immunity

Article References: Zhang, J., Chen, C., Mu, Q., Hou, Y., & Zhang, X. (2026). Radiotherapy drives PD-1 expression on monocytes to attenuate anti-tumor immunity. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04519-4

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04519-4

Keywords: radiotherapy, PD-1, monocytes, tumor microenvironment, radioresistance, CD8-positive T cells, adenosine, A2A receptor, NF-kB, immunotherapy, cancer resistance, myeloid cells